Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 2,691 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Normal saline solution Clear all

Conditions: Upper Airway Obstruction
Interventions: Physostigmine, Oxygen, Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: IV Atropine and Fentanyl Premedication Arm, IV Normal Saline Placebo Arm; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 0 Hours to 72 Hours
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Postoperative Pain
Interventions: Extended-Release liposomal bupivacaine (Exparel), Normal saline; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Androgenetic Alopecia
Interventions: Decellularized allogeneic human amniotic fluid, Sodium chloride 0.9% injectable solution; Biological · Drug
Lead sponsor: Restore Biologics Holdings, Inc. dba Xtressé; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Orlando, Florida • Marriottsville, Maryland

Conditions: Herpes Zoster, Allergy and Immunology, Corona Virus Infection
Interventions: SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted), Normal Saline; Biological · Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 65 Years to 100 Years
Enrollment: 217 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Analgesic Adverse Reaction
Interventions: Ketorolac Tromethamine, 0.9% Normal Saline; Drug
Lead sponsor: Albany Medical College; Other
Eligibility: 2 Years to 18 Years
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Albany, New York

Conditions: Healthy Participants
Interventions: CDX-622, Normal Saline; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Corneal Ulcer
Interventions: Mesenchymal Stromal Cells, Control Solution; Biological · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Recurrent Ovarian Cancer, Fallopian Tube Cancer
Interventions: Cisplatin, Doxorubicin; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Disease
Interventions: Dexmedetomidine, Placebo; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 798 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Delayed Graft Function
Interventions: BB3; Drug
Lead sponsor: Angion Biomedica Corp; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 6
States / cities: San Diego, California • Washington D.C., District of Columbia • Baltimore, Maryland + 2 more

Conditions: Stroke, Ischemic
Interventions: Hydrogen, Minocycline, Placebo Hydrogen, Placebo Minocycline; Drug · Other
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Pitt Hopkins Syndrome
Interventions: MTP-101P, Vancomycin, Magnesium Citrate, Antacid, Placebo MTP-101P, Placebo Vancomycin; Combination Product
Lead sponsor: Gut-Brain-Axis Therapeutics Inc.; Other
Eligibility: 5 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Internal Disc Disruption
Interventions: Intradiscal PRP & BMC Injections; Procedure
Lead sponsor: Annu Navani; Other
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Campbell, California • Los Angeles, California • Tyler, Texas + 1 more

Conditions: Infertility
Interventions: Bravelle(follicle stimulating hormone), Saline ( placebo); Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Type 2 Diabetes Mellitus
Interventions: PF-06293620, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 7
States / cities: Chula Vista, California • DeLand, Florida • Orlando, Florida + 2 more

Conditions: Tachycardia, Chronic Orthostatic Intolerance
Interventions: Acetazolamide, Atomoxetine, NO Drug, Clonidine, Entacapone, Entacapone & Propranolol, Atomoxetine & Propranolol, Indomethacin, Mecamylamine, Isosorbide Dinitrate, Melatonin, Midodrine, Modafinil, Octreotide, Placebo, Propranolol, Modafinil & Propranolol, Sertraline, IV Saline, Drinking Water, Breathing Device, memantine, Abdominal binder; Drug · Other · Dietary Supplement + 3 more
Lead sponsor: Satish R. Raj; Other
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pain, Radiating
Interventions: Lidocaine, Lidocaine with Dexamethasone; Drug
Lead sponsor: OrthoCarolina Research Institute, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Osteoarthritis
Interventions: ACP, Placebo; Device · Other
Lead sponsor: Arthrex, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 4
States / cities: Chicago, Illinois • Ann Arbor, Michigan • Columbia, Missouri + 1 more

Conditions: Healthy
Interventions: WAL0921, Placebo; Drug
Lead sponsor: Walden Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cytomegalovirus Disease
Interventions: NPC-21 Low dose, NPC-21 High dose, NPC-21 Placebo; Drug
Lead sponsor: Nobelpharma; Industry
Eligibility: 18 Years to 76 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 14
States / cities: Phoenix, Arizona • La Mesa, California • Atlanta, Georgia + 9 more

Conditions: Insulin Resistance
Interventions: insulin infusion, Dextrose infusion, Saline Infusion; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 20 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Healthy
Interventions: Erythromycin, Placebo, Magnetic Resonance Imaging, Barium Sulfate Solution; Drug · Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Post Operative Pain Control
Interventions: Exparel 266 MG Per 20 ML Injection, Placebo; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Phamacological Reversal of Airway Instability During Sedation

Premedication for Less Invasive Surfactant Administration Study (PRELISA)

Efficacy of Extended-Release Liposomal Bupivacaine for Post-Operative Urogynecologic Surgery

XVIE to Treat Androgenetic Alopecia (AGA)

Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents

Ketorolac Use in Pediatric Patients Undergoing Tonsillectomy

A Phase I Study of CDX-622

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers

Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery

Study to Improve Renal Function After Kidney Transplantation

Neuroprotection in Acute Ischemic Stroke

Microbiota Transfer Therapy for Children and Adults With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders

The Use of PRP and BMC in Patients With Internal Disc Disruption Multicenter Prospective Randomized Controlled Trial in Patients With Internal Disc Disruption

Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial

A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus

Treatment of Orthostatic Intolerance

Surgery Prevention by Transforaminal Injection of Epidural Steroids for Cervical Radicular Pain

Autologous Conditioned Plasma (ACP) Intra-articular (IA) Injections for Knee Osteoarthritis (OA)

Single Ascending Dose Study of WAL0921 in Healthy Subjects

A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection

The Suppression of Toll Like Receptors by Insulin

Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility

Pectoralis and Serratus Muscle Blocks